Table 2.

Comorbidities and medication of AAA patients and controls in the diagnostic study

Comorbidity	Healthy (N = 37)	AAA (N = 40)	p value
	N (%)	N (%)
Hypertension	23 (62.2%)	34 (85.0%)	0.022
Hyperlipidaemia	11 (29.7%)	33 (82.5%)	< 0.001
PAD	4 (10.8%)	7 (17.5%)	0.402
Coronary heart disease	4 (10.8%)	14 (35.0%)	0.016
Myocardial infarction	3 (8.1%)	9 (22.5%)	0.082
Stroke	3 (8.1%)	2 (5.0%)	0.667
Diabetes mellitus	4 (10.8%)	9 (22.5%)	0.171
COPD	4 (10.8%)	14 (35.0%)	0.012
Anti-platelet therapy	12 (32.4%)	37 (92.5%)	< 0.001
Anti-coagulation therapy	6 (16.2%)	9 (22.5%)	0.487
Anti-hypertensive therapy	23 (62.2%)	34 (85.0%)	0.022
Lipid-lowering agents	6 (16.2%)	34 (85.0%)	< 0.001
Diabetic medication	4 (10.8%)	7 (17.5%)	0.402
	Median (IQR)	Median (IQR)
Framingham risk score [%]	23.6 (24.3)	30.4 (25.7)	0.031

AAA abdominal aortic aneurysm, COPD chronic obstructive pulmonary disease, IQR interquartile range, PAD peripheral artery occlusive disease